NEW YORK (GenomeWeb News) – Life Technologies today said that it has signed a licensing and supply deal with VelaDx providing the Singapore-based firm rights to develop clinical diagnostic tests on Life Tech's Ion Personal Genome Machine platform.

Under the terms of the deal VelaDx will seek regulatory approvals from global authorities to sell clinical tests for oncology and infectious disease applications. Further terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.